Endocrine Abstracts

Introduction: Dopamine agonists (DA) are first-line treatment for prolactinomas and effectively control hyperprolactinemia in most patients. However, side effects may negatively impact health-related quality of life; and post-withdrawal remission rates are low, resulting in prolonged DA treatment.Methods: Dutch multicenter prospective observational cohort study mapping standard care for 316 prolactinoma patients. Baseline clinical characteristics and tre...

Introduction: Patients with prolactinomas suffer from a wide range of symptoms, of which the effect on health-related quality of life (HR-QoL) needs further investigation. Moreover, the first-line treatment for patients with prolactinomas, dopamine agonists (DAs), albeit being effective in lowering prolactin levels, might further hamper HR-QoL due to side effects. To assess the impact of symptoms and treatment modality on HR-QoL, a cohort of patients with prolactinoma was cros...